



Member of the Medicine-Pharmaceutical Cluster NANOMEDIC

GENERI BIOTECH s.r.o.

Machkova 587, 500 11 Hradec Králové, Czech Republic

tel.: +420 495 056 353

fax: +420 495 056 316

e-mail: info@generi-biotech.com

www.generi-biotech.com

Company Registration No. 63221667

Tax Identification No. CZ63221667

Registered number of employees:	27
Revenues (millions of CZK):	30
Registered capital of the company (millions of CZK):	0,1
The proportion of exports in total revenues (in %):	1,63

Authorized representative of the company:

Dr. Radovan Haluza, Ph.D.

Authorized representative

e-mail: radovan.haluza@generi-biotech.com

Business agent of the company:

Rostislav Havran

Head of the marketing department

tel.: +420 495 056 353

fax: +420 495 056 316

e-mail: rostislav.havran@generi-biotech.com

Major markets abroad:

Czech Republic

Slovak Republic

Poland, Romania

GENERI BIOTECH s.r.o. is a Czech biotechnological company which was founded in 1995 and originally focused on the production of oligonucleotides. Its activities gradually extended to the two areas:

The production of commercial products and services:


- for molecular biology
 - oligonucleotides and probes
 - kits for gene expression determination
 - kits for microbial DNA detection and quantification
 - competent cells for cloning
 - kits for the detection of selected mutations in the human genome (the kit is currently subjected to the certification process for diagnostic use)
 - recombinant proteins for immunodiagnostics
 - molecular services (for example sequencing, qPCR positive controls, etc.)
- molecular biology services for private clients
 - biological relationship tests (paternity test) for courts of law (GENERI BIOTECH is an expert institute designated in 2005 by the Ministry of Justice) - www.otcovstvi-urceni.cz
 - biological relationship tests (paternity test) for private clients (www.p-test.cz) - anonymous paternity testing.

Research and development:

Research work at GENERI BIOTECH proceeds in the two main lines:

- the development of new DNA-detection systems particularly for the detection of microorganisms which can be used for example as potential bioterrorism agents or as weapons of mass destruction (DNA tools line)
- the development of innovated drugs and in vitro testing systems for potential drugs (drug discovery line)

Within the two above-mentioned areas of research, GENERI BIOTECH worked on several research and development projects.



THIS PROJECT IS CO-FUNDED BY THE EUROPEAN REGIONAL DEVELOPMENT FUND AND BY THE MINISTRY OF INDUSTRY AND TRADE OF THE CZECH REPUBLIC.

Member of the Medicine-Pharmaceutical Cluster NANOMEDIC

The majority of the company's current activities was established in order to obtain know-how for oligonucleotide synthesis. Oligonucleotides are short synthetic sections of DNA (deoxyribonucleic acid) which have a wide range of applications in molecular biology; in general, they can be used almost anywhere where one works with DNA. Their users include molecular biologists in different fields of life sciences: human and veterinary medicine, plant biology, microbiology, food technologies, pharmaceutical research, etc. Oligonucleotides serve as one of the key components for PCR (Polymerase Chain Reaction), which is currently the most frequently used research and diagnostic tool in the field of molecular biology and genetics.

Other above-mentioned products for molecular biology are based mainly on the production of oligonucleotides, various biotechnological components for molecular biology, real-time PCR kits, recombinant proteins, bioinformatics and cloning services. Apart from oligonucleotides, all other products result from our own research and development.

The company provides the cluster members with molecular biological genetic services, and ensures the production of biotechnological components for molecular biology. It develops diagnostic agents based on molecular biology and does research into potential therapeutic agents in the field of gene therapy.

